Syndax Pharmaceuticals (SNDX) Current Assets (2015 - 2026)

Syndax Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $471.2 million for Q1 2026.

• In Q1 2026, Current Assets fell 14.14% year-over-year to $471.2 million; the TTM figure through Mar 2026 stood at $471.2 million (down 14.14% YoY), while the FY2025 annual figure was $528.1 million, down 12.43% from the prior year.
• Current Assets was $471.2 million for Q1 2026 at Syndax Pharmaceuticals, down from $528.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $603.1 million in Q4 2024 to a low of $357.6 million in Q3 2022.
• Historically, Current Assets has averaged $470.6 million across 5 years, with a median of $453.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Current Assets jumped 50.59% in 2022, then dropped 14.14% in 2026.
• A 5-year view of Current Assets shows it stood at $489.8 million in 2022, then climbed by 18.6% to $580.9 million in 2023, then advanced by 3.82% to $603.1 million in 2024, then retreated by 12.43% to $528.1 million in 2025, then retreated by 10.78% to $471.2 million in 2026.
• The last three Current Assets figures came in at $471.2 million (Q1 2026), $528.1 million (Q4 2025), and $529.8 million (Q3 2025), per Business Quant data.